A highly potent antibody effective against SARS-CoV-2 variants of concern

Control of the ongoing SARS-CoV-2 pandemic is endangered by the emergence of viral variants with increased transmission efficiency, resistance to marketed therapeutic antibodies, and reduced sensitivity to vaccine-induced immunity. Here, we screen B cells from COVID-19 donors and identify P5C3, a hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenwick, Craig, Turelli, Priscilla, Perez, Laurent, Pellaton, Céline, Esteves-Leuenberger, Line, Farina, Alex, Campos, Jérémy, Lana, Erica, Fiscalini, Flurin, Raclot, Charlène, Pojer, Florence, Lau, Kelvin, Demurtas, Davide, Descatoire, Marc, Joo, Victor S., Foglierini, Mathilde, Noto, Alessandra, Abdelnabi, Rana, Foo, Caroline S., Vangeel, Laura, Neyts, Johan, Du, Wenjuan, Bosch, Berend-Jan, Veldman, Geertruida, Leyssen, Pieter, Thiel, Volker, LeGrand, Roger, Lévy, Yves, Trono, Didier, Pantaleo, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452523/
https://www.ncbi.nlm.nih.gov/pubmed/34599871
http://dx.doi.org/10.1016/j.celrep.2021.109814
Descripción
Sumario:Control of the ongoing SARS-CoV-2 pandemic is endangered by the emergence of viral variants with increased transmission efficiency, resistance to marketed therapeutic antibodies, and reduced sensitivity to vaccine-induced immunity. Here, we screen B cells from COVID-19 donors and identify P5C3, a highly potent and broadly neutralizing monoclonal antibody with picomolar neutralizing activity against all SARS-CoV-2 variants of concern (VOCs) identified to date. Structural characterization of P5C3 Fab in complex with the spike demonstrates a neutralizing activity defined by a large buried surface area, highly overlapping with the receptor-binding domain (RBD) surface necessary for ACE2 interaction. We further demonstrate that P5C3 shows complete prophylactic protection in the SARS-CoV-2-infected hamster challenge model. These results indicate that P5C3 opens exciting perspectives either as a prophylactic agent in immunocompromised individuals with poor response to vaccination or as combination therapy in SARS-CoV-2-infected individuals.

Ejemplares similares